Therapeutics testing covers a wide range of areas from controlled substance monitoring to pharmacogenomics (PGx). Our testing delivers clarity on drug use to advance understanding and improve patient outcomes. We provide access to Mayo Clinic experts and a test menu developed through evidence-driven clinical innovation to help clinicians guide patient care.
“The goal is not to identify every drug technically possible, but to perform medically necessary testing for those drugs that are most likely to impact clinical outcomes.”
Paul Jannetto, Ph.D., Director of the Clinical and Forensic Toxicology Lab, Clinical Mass Spectrometry Lab, and Metals Lab
Our difference
The latest
Ann Moyer, M.D., Ph.D., explains how Mayo Clinic Laboratories' unique genetic tests identify patients at high risk of severe reactions to fluoropyrimidines — a type of chemotherapy drug. Test results can guide clinical decision-making for safer cancer treatment.
In this month’s “Hot Topic,” Paul Jannetto, Ph.D., discusses the high-resolution targeted stimulant and PCP screening test from Mayo Clinic Laboratories, which offers sensitivity and specificity for use in the monitoring and management of patients who are prescribed CNS stimulant medications.
In this episode, Paul Jannetto, Ph.D., associate professor of laboratory medicine and pathology and director of the Clinical and Forensic Toxicology Lab, Clinical Mass Spectrometry Lab, and Metals Lab at Mayo Clinic, discusses how his three labs support toxicology testing for patient care.
Controlled substance testing options vary in the details they provide about patient drug use, painting an incomplete picture of usage patterns that can hinder accurate prescription monitoring and treatment outcomes. However, a new comprehensive Controlled Substance Monitoring Panel, developed by the Clinical and Forensic Toxicology Laboratory at Mayo Clinic Laboratories, offers in-depth analysis on more than 70 different prescription medications and illicit substances to provide clinicians with details and interpretations on patients’ controlled substance use lacking in other laboratory assays.
In this month’s “Hot Topic,” Paul Jannetto, Ph.D., discusses the high-resolution targeted opioid screening test from Mayo Clinic Laboratories, which offers sensitivity and specificity for use in the monitoring and management of patients who are prescribed opioid pain-relieving medication.
Ann Moyer, M.D., Ph.D. gives an overview of this new test available through Mayo Clinic Laboratories. She discusses when this testing should be ordered, how this testing improves upon other testing approaches, and what clinical action can be taken due to the results of this testing.
This “Phlebotomy” webinar reviews: Having a medical procedure or a lab draw can be fearful for children. Even if it is their first time or they have had a bad past experience, there are ways to make these procedures easier for children.
How Your Genes Determine which Medications Work Best for You The drugs available today to treat diseases are powerful agents that work as intended for[...]
Pharmacogenomic testing is still limited, despite ample research, the existence of guidelines, and the emerging evidence it can help patients. Ann Moyer, M.D., Ph.D., Co-Director of the Personalized Genomics Laboratory at Mayo Clinic in Rochester, Minnesota, makes a case for pharmacogenomics.
By taking into account an individual’s genes, lifestyle, and environment, precision medicine offers the prospect of finding individualized therapies that might ultimately cure diseases such as cancer and diabetes. Yet, as with other technological revolutions, precision medicine’s quest for innovation bumps up against a host of legal issues—for patients as well as laboratories and providers of care.